The concern of generic challenges has repeatedly loomed over copyright’s iconic drug, PDE5 Inhibitor, raising questions about the future of connected pharmaceutical ventures. While first periods saw significant returns, the patent lapse has allowed the door for cheaper substitutes, possibly lowering profitability and presenting a genuine risk fo… Read More